The complement system and its role in the treatment of ANCA-associated vasculitis
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.088Keywords
the complement system, C5a receptor inhibitor, AVV, AvacopanAbstract
Objective: This study aimed to evaluate the role of the complement system in a therapy of the ANCA- associated vasculitis.
Methods and materials: A literature search was conducted in the PubMed MEADLINE database of medical publications using the following keywords: the complement system, AVV, C5a inhibitor, avacopan
Results: The complement system is a crucial part of the human immune system. Its cascade is involved in the pathogenesis of many disease entities, especially those with an inflammatory response. As anaphylatoxin, this is especially true of the C5a protein. C5a receptors are distributed mainly on tissue inflammatory cells, e.g. macrophages, mast cells, and endothelial cells. Therefore a C5a receptor inhibitor may reduce the inflammatory response of the body. This mechanism is used by the Avacopan, a newly approved drug for the treatment of ANCA-associated vasculitis as the main indication. Tavneos (avacopan) was only introduced in the UE in January 2022, as the first new drug to treat AVV in over a decade.
Conclusion: The C5a receptor inhibitor – Avacopan might be the future of a glucocorticoids-free or glucocorticoids – low dose therapy of ANCA-associated vasculitis. As the ADVOCATE clinical trial shows, Avacopan was neither superior, nor inferior to prednisone tamper with respect to sustained remission at 26 weeks, but proved to be superior with sustaining remission at 52 weeks. All the patients received rituximab or cyclophosphamide as a form of therapy.
Keywords: the complement system; C5a receptor inhibitor, AVV; Avacopan
References
Liebrich W, Esser M. Complement Deficiency. Current Allergy and Clinical Immunology. 2022;30(4):276-277. doi:10.1016/b978-1-4377-1720-4.00080-7
Bardhan M, Kaushik R. Physiology, Complement Cascade. StatPearls. Published online May 8, 2022. Accessed August 18, 2022. https://www.ncbi.nlm.nih.gov/books/NBK551511/
C5a receptor antagonists - PubMed. Accessed August 20, 2022. https://pubmed.ncbi.nlm.nih.gov/10526086/
Wu KY, Cao B, Wang CX, et al. The C5a/C5aR1 Axis Contributes to the Pathogenesis of Acute Cystitis Through Enhancement of Adhesion and Colonization of Uropathogenic E. coli. Front Cell Infect Microbiol. 2022;12. doi:10.3389/FCIMB.2022.824505
Thorley J. FDA approves avacopan for ANCA-associated vasculitis. The Lancet Rheumatology. 2022;4(1):e21. doi:10.1016/s2665-9913(21)00391-x
CHMP. Tavneos INN-Avacopan. www.ema.europa.eu/contact
Fauci, Anthony S._ Hauser, Stephen L._ Jameson, J. Larry_ Kasper, Dennis L._ Longo, Dan Louis_ Loscalzo, Joseph - Harrison’s principles of internal medicine-McGraw Hill Education Medical (2015).
Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46(10):1615-1616. doi:10.1093/RHEUMATOLOGY/KEM146A
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis - Full Text View - ClinicalTrials.gov. Accessed August 20, 2022. https://clinicaltrials.gov/ct2/show/NCT02994927?term=avacopan&cond=ANCA+Associated+Vasculitis&rank=1
Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine. 2021;384(7):599-609. doi:10.1056/NEJMOA2023386/SUPPL_FILE/NEJMOA2023386_DATA-SHARING.PDF
Harigai M, Takada H. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol. 2022;32(3):475-483. doi:10.1093/MR/ROAB104
Markotačagalj A, Markotačagalj M, Marinovi´c BM, Bukvi´c Z, Mokos B. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. International Journal of Molecular Sciences 2022, Vol 23, Page 3753. 2022;23(7):3753. doi:10.3390/IJMS23073753
Sommerfeld O, Medyukhina A, Neugebauer S, et al. Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis. Mol Ther. 2021;29(1):338-346. doi:10.1016/J.YMTHE.2020.09.008
Deng Y, Zheng Y, Li D, et al. Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine. 2021;70:103477. doi:10.1016/J.EBIOM.2021.103477
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Natalia Rybak, Iga Dudek, Tomasz Skubel, Michał Dobrzyński, Jakub Czarnota, Małgorzata Drozd
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 433
Number of citations: 0
